期刊文献+

巯嘌呤口服混悬液有关物质的HPLC法测定 被引量:1

Determination of Related Substances in Thiopurine Oral Suspension by HPLC
下载PDF
导出
摘要 建立了HPLC法测定巯嘌呤口服混悬液中的有关物质,以加校正因子的自身对照法定量。采用Uitimate Phenyl-Ether色谱柱,以0.04%甲酸∶甲醇为流动相,等度洗脱,检测波长260 nm。计算有关物质的相对校正因子(RCF),以此计算有关物质含量,并与对照品法测定结果比较,以验证方法的准确性。结果主成分巯嘌呤与相邻杂质,以及各杂质之间均分离良好,RCF法与对照品法测定结果无显著性差异。已知杂质2、3的相对保留时间分别为0.56和4.33,相对校正因子分别为0.16和0.23,2和3的平均加样回收率为104.2%和95.3%,RSD为3.2%和2.9%。本方法重复性好、灵敏度高,适用于巯嘌呤口服混悬液中有关物质的分析。 a hplc method was established for the determination of related substances in mercaptopurine oral suspension,with self-control method added with correction factors.A Uitimate Phenyl-Ether chromatographic column was used with 0.04%formic acid:methanol as mobile phase,and the detection wavelength was 260nm.The relative correction factor(RCF)of related substances is calculated to calculate the content of related substances,and compared with the determination results of the reference substance method to verify the accuracy of the method.Results The main component mercaptopurine was well separated from its neighboring impurities,and there was no significant difference between RCF method and control method.It is known that the relative retention times of impurities 2 and 3 are 0.56 and 4.33 respectively,the relative correction factors are 0.16 and 0.23 respectively,and the average recovery rates of impurities 2 and 3 are 104.2%and 95.3%,RSD are 3.2%and 2.9%.The method has good repeatability and high sensitivity,and is suitable for the analysis of related substances in mercaptopurine oral suspension.
作者 张薇 朱婷 Zhang Wei;Zhu Ting(Nanjing Zeheng Pharmaceutical Technology Development Co.,Ltd.,Nanjing 210046,China)
出处 《云南化工》 CAS 2018年第12期63-64,共2页 Yunnan Chemical Technology
关键词 巯嘌呤 相对校正因子 有关物质 HPLC mercaptopurine Relative correction factor Related substances HPLC
  • 相关文献

参考文献1

二级参考文献18

  • 1魏红,黄民,李智毅,张祯,张建萍,吴珏珩.中国哈萨克族人硫嘌呤甲基转移酶活性分布和基因多态性[J].中国临床药理学杂志,2005,21(6):423-426. 被引量:8
  • 2Levinsen M, Rosthoj S, Nygaard U, et al. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity [J]. Cancer Chemother Pharmacol, 2015, 75(1): 59-66.
  • 3ANielsen SN, Frandsen TL, Nersting J, et al. Pharmacokineticsof 6-thioguanine and 6-mercaptopurine combination maintenance therapy of childhood ALL: hypothesis and case report [J]. J Pediatr Hematol Oncol, 2015, 37(3): e206-e209.
  • 4Roberts RL, Wallace MC, Seinen ML, et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease [J]. Am J Gastroenterol, 2014, 109(6): 925-927.
  • 5Lennard L, Cartwright CS, Wade R, et al. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003 [J]. Br J Haematol, 2015, 170(4): 550-558.
  • 6Moreno-Guerrero SS, Ramirez-Pacheco A, Dorantes- Acosta EM, et al. An~ilisis de los polimorfismos g6nicos de tiopttrina S-metiltransferasa (TPMT) en pacientes pedi~itricos mexicanos con cancer [J]. Rev Invest Clin, 2013, 65(2): 156- 164.
  • 7Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and "3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus [J]. Br J Clin Pharmacol, 2001, 51(5): 475-477.
  • 8Farfan MJ, Salas C, Canales C, et al. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia [J/OL]. BMC Cancer, 2014, 14:299 [2015-09-02]. http:// www.biomedcentral.com/contenffpdf/1471-2407-14-299.pdf.
  • 9Pui CH, Evans WE. Treatment of acute lymphoblastie leukemia [J]. N Engl J Med, 2006, 354(2): 166-178.
  • 10Katsanos KH, Papadakis KA. Pharmacogenetics of inflammatory bowel disease [J]. Pharmacogenomics, 2014, 15(16): 2049-2062.

共引文献5

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部